Literature DB >> 22692587

Chemotherapy patients with C. difficile colitis have outcomes similar to immunocompetent C. difficile patients.

David B Stewart1, Emmanuel Yacoub, Junjia Zhu.   

Abstract

BACKGROUND: Clostridium difficile colitis (CDC) patients receiving chemotherapy for hematologic malignancies are anticipated to have worse outcomes than immunocompetent CDC patients. STUDY
DESIGN: An IRB approved retrospective cohort study (2004-2009) identified an equal number (n = 49) of CDC inpatients receiving chemotherapy for hematologic malignancies (CDC-HM) as well as CDC patients without malignancies (CDC-NM). Chi-squared tests, linear regression, and analysis of variance were used to compare outcomes.
RESULTS: No difference (p > 0.05) was noted between groups regarding age, hypertension, diabetes, COPD, or coronary artery disease. Approximately 62 % of CDC-HM patients required colony-stimulating factor for neutropenia. There was no difference (p > 0.05) in peak lactate or creatinine levels. None of the CDC-HM group required colectomy, while four CDC-NM patients required surgery (p = 0.04); neither group experienced death. No differences were noted regarding need for ICU admission for CDC or the need for vasopressors (p > 0.05). Mean hospital length of stay was longer for the CDC-HM group (22 days vs. 10 days; p = 0.001).
CONCLUSIONS: CDC-HM patients had longer lengths of stay than CDC-NM patients without an increase in rates of death, colectomy, or ICU admission. Outcomes in CDC-HM are better than many would anticipate, underscoring the current knowledge deficit regarding C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22692587     DOI: 10.1007/s11605-012-1930-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  26 in total

1.  Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function.

Authors:  Gerly A C Brito; Gail W Sullivan; William P Ciesla; Holliday T Carper; Gerald L Mandell; Richard L Guerrant
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

2.  Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma.

Authors:  J I Arango; A Restrepo; D L Schneider; N S Callander; J L Ochoa-Bayona; M I Restrepo; P Bradshaw; J Patterson; C O Freytes
Journal:  Bone Marrow Transplant       Date:  2006-03       Impact factor: 5.483

3.  Determination and validation of a predictive model for Clostridium difficile diarrhea in hospitalized oncology patients.

Authors:  K Hornbuckle; A Chak; H M Lazarus; G S Cooper; L A Kutteh; R Gucalp; P S Carlisle; J Sparano; P Parker; R A Salata
Journal:  Ann Oncol       Date:  1998-03       Impact factor: 32.976

4.  Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells.

Authors:  Clara Maria Ausiello; Marina Cerquetti; Giorgio Fedele; Fabiana Spensieri; Raffaella Palazzo; Maria Nasso; Simona Frezza; Paola Mastrantonio
Journal:  Microbes Infect       Date:  2006-08-08       Impact factor: 2.700

5.  A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group.

Authors:  O Karlström; B Fryklund; K Tullus; L G Burman
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

Review 6.  Clostridium difficile.

Authors:  L Kyne; R J Farrell; C P Kelly
Journal:  Gastroenterol Clin North Am       Date:  2001-09       Impact factor: 3.806

7.  Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis.

Authors:  Graeme S Cottrell; Silvia Amadesi; Stella Pikios; Eric Camerer; J Adam Willardsen; Brett R Murphy; George H Caughey; Paul J Wolters; Shaun R Coughlin; Anders Peterson; Wolfgang Knecht; Charalabos Pothoulakis; Nigel W Bunnett; Eileen F Grady
Journal:  Gastroenterology       Date:  2007-04-13       Impact factor: 22.682

8.  Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes.

Authors:  Erik R Dubberke; Kimberlay A Reske; Anand Srivastava; Justin Sadhu; Robert Gatti; Rebecca M Young; Lauren C Rakes; Brian Dieckgraefe; John DiPersio; Victoria J Fraser
Journal:  Clin Transplant       Date:  2009-07-13       Impact factor: 2.863

9.  Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection.

Authors:  C R Clabots; S Johnson; M M Olson; L R Peterson; D N Gerding
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

10.  Clostridium difficile infection in patients with haematological malignant disease. Risk factors, faecal toxins and pathogenic strains.

Authors:  S R Heard; B Wren; M J Barnett; J M Thomas; S Tabaqchali
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

View more
  11 in total

1.  Predictors of mortality attributable to Clostridium difficile infection in patients with underlying malignancy.

Authors:  Young Kyung Yoon; Min Ja Kim; Jang Wook Sohn; Hye Suk Kim; Yoon Ji Choi; Jung Sun Kim; Seung Tae Kim; Kyong Hwa Park; Seok Jin Kim; Byung Soo Kim; Sang Won Shin; Yeul Hong Kim; Yong Park
Journal:  Support Care Cancer       Date:  2014-03-05       Impact factor: 3.603

2.  Vancomycin Use for Pediatric Clostridium difficile Infection Is Increasing and Associated with Specific Patient Characteristics.

Authors:  Hayden T Schwenk; Dionne A Graham; Tanvi S Sharma; Thomas J Sandora
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

Review 3.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 4.  Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection.

Authors:  Edwin Vargas; Senu Apewokin; Rajat Madan
Journal:  Anaerobe       Date:  2017-02-20       Impact factor: 3.331

5.  Risk factors associated with Clostridium difficile infection in adult oncology patients.

Authors:  Analia Rodríguez Garzotto; Antonio Mérida García; Nerea Muñoz Unceta; M Mar Galera Lopez; M Ángeles Orellana-Miguel; C Vanesa Díaz-García; Susana Cortijo-Cascajares; Hernán Cortes-Funes; M Teresa Agulló-Ortuño
Journal:  Support Care Cancer       Date:  2014-11-20       Impact factor: 3.603

6.  Outcomes of Clostridioides difficile infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study.

Authors:  Bojana Milenković; Vesna Šuljagić; Aneta Perić; Viktorija Dragojević-Simić; Olivera Tarabar; Milomir Milanović; Vesna Putić; Diana Tomić; Branislava Miljković; Sandra Vezmar Kovačević
Journal:  Eur J Hosp Pharm       Date:  2021-02-12

7.  Poorer outcomes among cancer patients diagnosed with Clostridium difficile infections in United States community hospitals.

Authors:  Andrew Delgado; Ivan A Reveles; Felicia T Cabello; Kelly R Reveles
Journal:  BMC Infect Dis       Date:  2017-06-23       Impact factor: 3.090

8.  Risk factors for Clostridium difficile infection in hemato-oncological patients: A case control study in 144 patients.

Authors:  Thorsten Fuereder; Danjel Koni; Andreas Gleiss; Michael Kundi; Athanasios Makristathis; Christoph Zielinski; Christoph Steininger
Journal:  Sci Rep       Date:  2016-08-11       Impact factor: 4.379

9.  Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.

Authors:  Yuji Akiyama; Akira Sasaki; Fumitaka Endo; Haruka Nikai; Satoshi Amano; Akira Umemura; Shigeaki Baba; Takehiro Chiba; Toshimoto Kimura; Takeshi Takahara; Hiroyuki Nitta; Koki Otsuka; Masaru Mizuno; Yusuke Kimura; Keisuke Koeda; Takeshi Iwaya
Journal:  World J Surg Oncol       Date:  2018-07-02       Impact factor: 2.754

Review 10.  Epidemiology of infections in cancer patients.

Authors:  Teresa R Zembower
Journal:  Cancer Treat Res       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.